The missing link in Bangladesh’s innovation economy
Why translating promising research into investable companies requires its own institutions, capabilities, and disciplined decisions.
Read articleDrug development · Portfolio strategy · Company building
Science.
Strategy.
Judgment.
I work at the intersection of science, strategy, and capital—turning scientific possibility into development programs and helping determine which opportunities deserve investment.
Executive practice
Drug development. Portfolio decisions. Venture building.
Intellectual work
Leadership and consequential decisions under uncertainty.
Ideas in public
Selected writing
Buying Evidence You Cannot Use
Capital allocation should preserve the ability to act on new evidence. A practical examination of commitments, uncertainty, and the options that remain after an experiment.
Read articleThe New Scarcity
AI can expand the set of credible options faster than an organization can act on them. The scarce resources become judgment, attention, and the capacity to commit.
Read article
A book in development
Before Strategy
Better strategy begins with better judgment.
An exploration of the orientation, questions, and choices that precede strategic action—and the discipline to learn as the evidence changes.
Explore the bookFrom science to strategy
Evidence. Decisions.
Consequences.
My work spans translational development, portfolio strategy, AI-enabled discovery, human-relevant disease models, and early-stage biotech company building.
I lead project and portfolio strategy at Greenstone Biosciences and serve as an advisor to Accanito Therapeutics and Magnet Ventures. My scientific foundation spans doctoral training at Toronto, research at Vanderbilt, and an academic affiliation at Stanford.
Read my biographyExplore the work
- Scientific publications
Molecular and cellular biology, signaling, and human-relevant drug development.
- Media & conversations
Where AI should actually earn its keep in biopharma — an Emerj conversation.
- Advisory interests
Translational strategy, portfolio diligence, and early company formation.